Skip to search formSkip to main contentSkip to account menu

Ribozyme RPI.4610

Known as: RPI-4610, RPI.4610, RPI4610 
A nuclease-stabilized synthetic ribozyme (ribonucleic acid enzyme) with potential anti-angiogenesis activity. Ribozyme RPI.4610 specifically… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Angiozymeanti-FLT-1 ribozyme

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
Serum and plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis in patients with metastatic breast… 
Review
2007
Review
2007
New agents for treatment of advanced transitional cell carcinoma.
The prognosis for any patient with progressive or recurrent invasive transitional cell carcinoma remains poor. In this context… 
2004
2004
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
PurposeRPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
1998
1998
News and Comments
Dr J. G. Duncan. Radiological diagnosis of metabolic bone disease. The metabolic bone diseases which were discussed were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License